• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by AtriCure Inc.

    3/26/26 4:11:09 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care
    Get the next $ATRC alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 6)


    AtriCure Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)




    04963C209

    (CUSIP Number)
    03/13/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    04963C209


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:   On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    AtriCure Inc
    (b)Address of issuer's principal executive offices:

    7555 Innovation Way, Mason, OH, 45040
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd.,, Malvern, PA, 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    0
    (b)Percent of class:

    0  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:03/26/2026
    Get the next $ATRC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATRC

    DatePrice TargetRatingAnalyst
    2/18/2026Outperform → Perform
    Oppenheimer
    2/11/2026$36.00Overweight → Neutral
    Analyst
    12/17/2024$40.00Overweight
    Analyst
    4/23/2024$32.00Perform → Outperform
    Oppenheimer
    10/23/2023$60.00Mkt Outperform
    JMP Securities
    9/29/2023$56.00Buy
    UBS
    2/16/2022$120.00 → $88.00Buy
    Canaccord Genuity
    2/16/2022$92.00 → $79.00Buy
    Needham
    More analyst ratings

    $ATRC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AtriCure to Participate in the Citizens Life Sciences Conference

    AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Citizens Life Sciences Conference. AtriCure's management is scheduled to participate in a fireside chat on Tuesday, March 10, 2026, at 1:05 p.m. Eastern Time. Interested parties may access a live audio webcast by visiting the "Investors" section of the company's website at https://ir.atricure.com. About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more tha

    2/24/26 8:00:00 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results

    Fourth Quarter 2025 worldwide revenue of $140.5 million – an increase of 13.1% year over year Fourth Quarter 2025 net income of $1.8 million and positive adjusted EBITDA of $19.9 million Full Year 2025 worldwide revenue of $534.5 million – an increase of 14.9% year over year Full Year 2025 net loss of $11.4 million and positive adjusted EBITDA of $61.8 million 2025 growth marked by expanding use of new products, including cryoSPHERE® MAX™ and AtriClip FLEX-Mini®, and the continued adoption of EnCompass® clamp AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-o

    2/17/26 4:01:00 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    AtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results

    AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, February 17, 2026, to discuss its fourth quarter and full year 2025 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio

    1/27/26 8:00:00 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    $ATRC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Privitera Salvatore bought $111,250 worth of shares (5,000 units at $22.25), increasing direct ownership by 5% to 103,290 units (SEC Form 4)

    4 - AtriCure, Inc. (0001323885) (Issuer)

    5/31/24 4:12:34 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    $ATRC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Doraiswamy Vinayak sold $149,150 worth of shares (5,000 units at $29.83), decreasing direct ownership by 5% to 96,875 units (SEC Form 4)

    4 - AtriCure, Inc. (0001323885) (Issuer)

    3/16/26 8:14:35 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    Director White Robert S. exercised 10,000 shares at a strike of $14.99, increasing direct ownership by 9% to 122,174 units (SEC Form 4)

    4 - AtriCure, Inc. (0001323885) (Issuer)

    3/12/26 8:52:43 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    President, CEO, & Director Carrel Michael H gifted 6,000 shares, decreasing direct ownership by 0.76% to 778,498 units (SEC Form 4)

    4 - AtriCure, Inc. (0001323885) (Issuer)

    3/9/26 8:32:37 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    $ATRC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by AtriCure Inc.

    SCHEDULE 13G/A - AtriCure, Inc. (0001323885) (Subject)

    3/26/26 4:11:09 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by AtriCure Inc.

    10-K - AtriCure, Inc. (0001323885) (Filer)

    2/19/26 12:39:55 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    AtriCure Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AtriCure, Inc. (0001323885) (Filer)

    2/17/26 4:00:15 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    $ATRC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    AtriCure downgraded by Oppenheimer

    Oppenheimer downgraded AtriCure from Outperform to Perform

    2/18/26 7:52:06 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    AtriCure downgraded by Analyst with a new price target

    Analyst downgraded AtriCure from Overweight to Neutral and set a new price target of $36.00

    2/11/26 7:49:25 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    Analyst resumed coverage on AtriCure with a new price target

    Analyst resumed coverage of AtriCure with a rating of Overweight and set a new price target of $40.00

    12/17/24 7:29:01 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    $ATRC
    Financials

    Live finance-specific insights

    View All

    AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results

    Fourth Quarter 2025 worldwide revenue of $140.5 million – an increase of 13.1% year over year Fourth Quarter 2025 net income of $1.8 million and positive adjusted EBITDA of $19.9 million Full Year 2025 worldwide revenue of $534.5 million – an increase of 14.9% year over year Full Year 2025 net loss of $11.4 million and positive adjusted EBITDA of $61.8 million 2025 growth marked by expanding use of new products, including cryoSPHERE® MAX™ and AtriClip FLEX-Mini®, and the continued adoption of EnCompass® clamp AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-o

    2/17/26 4:01:00 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    AtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results

    AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2025 financial results on Tuesday, February 17, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, February 17, 2026, to discuss its fourth quarter and full year 2025 financial results. Those interested in listening to the conference call should register online using this link. Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the audio

    1/27/26 8:00:00 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026

    AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2025 and provided 2026 financial guidance. Preliminary, unaudited revenue for fourth quarter 2025 is expected to be $140.5 million, reflecting growth of approximately 13% over the fourth quarter of 2024 (12% on a constant currency basis). U.S. revenue is expected to be $114.3 million, reflecting growth of approximately 13%, and international revenue is expected to be $26.2 million, an increase of approximately 15% as

    1/12/26 10:21:00 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    $ATRC
    Leadership Updates

    Live Leadership Updates

    View All

    AtriCure Appoints Shlomi Nachman to the Board of Directors

    AtriCure, Inc. (NASDAQ:ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced it appointed Shlomi Nachman to its Board of Directors. Mr. Nachman's long and distinguished career in the medical device industry has placed him at the forefront of new market development and growth, serving most recently as Company Group Chairman within Johnson & Johnson's Medical Devices business. Mr. Nachman has over 25 years of experience in the medical device industry and is currently on the board of several private medical device companies, as well as the Arnold and Mable Beck

    1/4/24 8:00:00 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    AtriCure Announces the Appointment of Deborah Yount as Chief Human Resources Officer

    AtriCure, Inc. ((ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced the appointment of Deborah Yount as Chief Human Resources Officer, effective today. Ms. Yount will have responsibility for global Human Resources activities. "We are excited to have Deborah joining us at AtriCure," said Michael Carrel, President and Chief Executive Officer. "She brings an incredible amount of industry and human capital expertise as we enter a period of accelerated growth. Our opportunities to address the global Afib epidemic and help patients manage post-operative pain are profo

    6/1/22 8:00:00 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    $ATRC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by AtriCure Inc.

    SC 13G - AtriCure, Inc. (0001323885) (Subject)

    11/14/24 8:00:04 AM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by AtriCure Inc. (Amendment)

    SC 13G/A - AtriCure, Inc. (0001323885) (Subject)

    2/14/24 2:56:38 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by AtriCure Inc. (Amendment)

    SC 13G/A - AtriCure, Inc. (0001323885) (Subject)

    2/13/24 4:58:56 PM ET
    $ATRC
    Medical/Dental Instruments
    Health Care